Back to top

oncology-screening: Archive

Zacks Equity Research

GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal

Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.

CRMDNegative Net Change MRUSPositive Net Change KNSANegative Net Change GMABNegative Net Change

Zacks Equity Research

OLMA Stock Soars 47% in September So Far on Second PFE Deal

Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.

AZNNegative Net Change NVSNegative Net Change PFENegative Net Change OLMANegative Net Change

Ahan Chakraborty

Will LLY's Oncology Portfolio Provide Key Diversification Benefits?

Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.

AZNNegative Net Change PFENegative Net Change MRKPositive Net Change LLYPositive Net Change